Current issues in schizophrenia: Overview of patient acceptability, functioning capacity and quality of life

CNS Drugs

Volumn 18, Issue SUPPL. 2, 2004, Pages 5-17

  Lambert, Martin ^a   Naber, Dieter ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

AKATHISIA; AKINESIA; ANHEDONIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BODY WEIGHT DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONSCIOUSNESS DISORDER; DEPRESSION; DISEASE SEVERITY; DRUG TOLERABILITY; DYSPHORIA; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; HEALTH STATUS; HUMAN; LEARNING DISORDER; MEMORY DISORDER; MENTAL FUNCTION; MENTAL HEALTH; MOTOR DYSFUNCTION; NEUROLEPTIC INDUCED DEFICIT SYNDROME; PARKINSONISM; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERCEPTION; PERSONALITY; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SELF ESTEEM; SELF REPORT; SEXUAL DYSFUNCTION; SOCIAL PSYCHOLOGY; SOCIAL STATUS; SOCIAL SUPPORT; THOUGHT DISORDER; WELLBEING;

ANTIPSYCHOTIC AGENTS; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PERSONAL SATISFACTION; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 3042704513     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418002-00002     Document Type: Conference Paper

References (85)

1. Albrecht GL, Fitzpatrick R, editors. A sociological perspective on health-related quality of life research. In: Advances in medical sociology - quality of life in health care. London: Jai Press; 1994
2. Lehman AF. The effects of psychiatric symptoms on quality of life assessments among the chronic mentally ill. Eval Prog Plann 1983; 6:143-51
3. Malm U, May PR, Dencker SJ. Evaluation of the quality of life of the schizophrenic outpatient: a checklist. Schizophr Bull 1981; 7:477-87
4. Bullinger M, Hasford J. Evaluating quality-of-life measures for clinical trials in Germany. Control Clin Trials 1991; 12 (4 Suppl.):91S-105S
5. Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Commun Psychiatry 1992; 43:262-5
6. Zissi A, Barry MM, Cochrane R. A mediational model of quality of life for individuals with severe mental health problems. Psychol Med 1998; 28:1221-30
7. Ritsner M, Ben-Avi I, Ponizovsky A, et al. Quality of life and coping with schizophrenia symptoms. Qual Life Res 2003; 12:1-9
8. Ritsner M, Ponizovsky A, Endicott J, et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 2002; 12:31-8
9. Ritsner M, Kurs R. Quality of life outcomes in mental illness: schizophrenia, mood and anxiety disorders. Expert Rev Pharmacoecon Outcomes Res 2003; 3:89-99
10. Angermeyer MC, Holzinger A, Kilian R, et al. Quality of life - as defined by schizophrenic patients and psychiatrists. Int J Soc Psychiatry 2001; 47:34-42
11. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19:609-18
12. Noll RL, Hoenkamp E, Nolen WA. Subjectieve bijwerkingen van neuroleptics. Nederlands Tijdschrift voor Geneeskunde 1991; 135:2113-6
13. de Haan L. Patients perspectives, subjective experiences and attitudes of patients with recent onset schizophrenia. Amsterdam: University of Amsterdam; 2001.
14. Van Putten T, May RP. 'Akinetic depression' in schizophrenia. Arch Gen Psychiatry 1978; 35:1101-7
15. Wise RA. Neuroleptic-induced anhedonia. Recent studies. In: Tamminga CA, Schulz SC, editors. Advances in neuropsychiatry and psychopharmacology. New York: Raven Press; 1991. pp. 323-31
16. Emerich DF, Sanberg PR. Neuroleptic dysphoria. Biol Psychiatry 1991; 29:201-3
17. Lewander T. Neuroleptics an the neuroleptic-induced deficit syndrome. Acta Psychiatrica Scand 1994; 380 (Suppl.):8-13
18. Lambert M, Schimmelman B, Karow A, et al. Subjective well-being under neuroleptic treatment - concepts measurement, clinical relevance and implications for antipsychotic treatment. Pharmacopsychiatry 2003; 36 (Suppl. 3): 181-90
19. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10 (Suppl. 3): 133-8
20. Awad AG. Antipsychotic medications in schizophrenia: how satisfied are our patients? Management issues in schizophrenia: patient satisfaction, compliance and outcomes in schizophrenia. Clear Perspect 1999; 2:1-6
21. Cabeza IG, Amador MS, Lopez CA, et al. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000; 41:349-55
22. Browne S, Garavan J, Gervin M, et al. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 1998; 186:74-8
23. Voruganti L, Heslegrave R, Awad AG, et al. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 1998; 28:165-72
24. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-83
25. Diamond R, Becker M. The Wisconsin Quality of Life Index: a multidimensional model for measuring quality of life. J Clin Psychiatry 1999; 60 (Suppl. 3):29-31
26. Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19:787-805
27. Oliver JP, Huxley PJ, Priebe S, et al. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Soc Psychiatry Psychiatr Epidemiol 1997; 32:76-83
28. Pukrop R, Moller HJ, Sass H, et al. Quality of life. Construct validation and the development of a modular system. Nervenartz 1999; 70:41-53
29. Lehman AF. A quality of life interview for the chronically mentally ill. Eval Program Plann 1988; 11:51-62
30. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388-98
31. Jaeger J, Bitter I, Czobor P, et al. The measurement of subjective experience in schizophrenia: the subjective deficit syndrome scale. Comprehen Psychiatry 1990; 31:216-26
32. Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Dis Nerv Syst 1976; 37:191-6
33. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13:177-83
34. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50:79-88
35. Voruganti LN, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 2002; 56:37-46
36. Carpiniello B, Lai GL, Pariante CM, et al. Symptoms, standards of living and subjective quality of life: a comparative study of schizophrenic and depressed outpatients. Acta Psychiatrica Scand 1997; 96:235-41
37. Skantze K, Malm U, Dencker SJ, et al. Comparison of quality of life with standard of living in schizophrenic out-patients. Br J Psychiatry 1992; 161:797-801
38. Lehman AF, Postrado LT, Rachuba LT. Convergent validation of quality of life assessments for persons with severe mental illnesses. Qual Life Res 1993; 2:327-33
39. Hansson L, Middelboe T, Merinder L, et al. Predictors of subjective quality of life in schizophrenic patients living in the community. A Nordic multicentre study. Int J Soc Psychiatry 1999; 45:247-58
40. Browne S, Clarke M, Gervin M, et al. Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry 2000; 176:173-6
41. Ritsner M, Kurs R, Gibel A, et al. Predictors of quality of life in major psychoses: a naturalistic follow-up study. J Clin Psychiatry 2003; 64:308-15
42. Awad AG, Hogan TP, Voruganti LN, et al. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 10 (Suppl. 3):123-32
43. de Haan L, Weisfelt M, Dingemans PM, et al. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (Berl) 2002; 162:24-8
44. Ritsner M. Predicting changes in domain-specific quality of life of schizophrenia patients. J Nerv Ment Dis 2003; 191:287-94
45. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999; 46:365-73
46. Huppert JD, Smith TE. Longitudinal analysis of subjective quality of life in schizophrenia: anxiety as the best symptom predictor. J Nerv Ment Dis 2001; 189:669-75
47. Bow-Thomas CC, Velligan DI, Miller AL, et al. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Res 1999; 86:131-42
48. Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996; 94:118-24
49. Giner J, Ibanez E, Cervera S, et al. Subjective experience and quality of life in schizophrenia [in Spanish]. Actas Esp Psiquiatr 2001; 29:233-42
50. Ho BC, Nopoulos P, Flaum M, et al. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998; 155:1196-201
51. Moritz S, Krausz M, Gottwalz E, et al. Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics. Psychopathology 2000; 33:48-51
52. Heslegrave RJ, Awad AG, Voruganti LN. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neurosci 1997; 22:235-43
53. Kaiser W. Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life. Br J Psychiatry 2000; 176:92-3
54. Aksaray G, Oflu S, Kaptanoglu C, et al. Neurocognitive deficits and quality of life in outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:1217-9
55. Brekke JS, Kohrt B, Green MF. Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophr Bull 2001; 27:697-708
56. Norman RM, Malla AK, McLean T, et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand 2000; 102:303-9
57. Ritsner M, Modai I, Endicott J, et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 2000; 61:880-9; quiz 90
58. Doyle M, Flanagan S, Browne S, et al. Subjective and external assessments of quality of life in schizophrenia: relationship to insight. Acta Psychiatr Scand 1999; 99:466-72
59. Lysaker PH, Bell MD, Bryson GJ, et al. Insight and interpersonal function in schizophrenia. J Nerv Ment Dis 1998; 186:432-6
60. Day JC, Kinderman P, Bentall R. A comparison of patients' and prescribes' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand 1998; 97:93-7
61. Gervin M, Browne S, Garavan J, et al. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 1999; 14:405-9
62. Lambert M, Conus P, Eide P, et al. Impact of present and past side effects on the attitude towards typical antipsychotic treatment. European Psychiatry submitted.
63. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 1987; 48 (Suppl.):13-9
64. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54:565-7
65. Hofer A, Kemmler G, Eder U, et al. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002; 63:49-53
66. Knudstorp TB, Gerlach J. Quality of life (QoL) in chronic schizophrenic patients related to symptoms, side-effects and subjective distress. In: Proceedings of the XIth World Congress on Psychiatry. Hamburg, Germany, 1999
67. Jarema M, Murawiec S, Szafranski T, et al. Subjective and objective evaluation of treating schizophrenia with classic or atypical drugs [in Polish]. Psychiatr Pol 2001; 35:5-19
68. Van Putten T, May PR, Marder SR. Response to antipsychotic medication: the doctor's and the consumer's view. Am J Psychiatry 1984; 141:16-9
69. Ritsner M, Modai I, Ponizovsky A. Assessing psychological distress in psychiatric patients: validation of the Talbieh Brief Distress Inventory. Compr Psychiatry 2002; 43:229-34
70. Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 2001; 16:153-62
71. Lasalvia A, Ruggeri M, Santolini N. Subjective quality of life: its relationship with clinician-rated and patient-rated psychopathology. The South-Verona Outcome Project 6. Psychother Psychosom 2002; 71:275-84
72. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 1993; 22:39-44
73. Eklund M, Backstrom M, Hansson L. Personality and self-variables: important determinants of subjective quality of life in schizophrenia out-patients. Acta Psychiatr Scand 2003; 108:134-43
74. Bechdolf A, Klosterkotter J, Hambrecht M, et al. Determinants of subjective quality of life in post acute patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2003; 253:228-35
75. Bengtsson-Tops A, Hansson L. Quantitative and qualitative aspects of the social network in schizophrenic patients living in the community. Relationship to sociodemographic characteristics and clinical factors and subjective quality of life. Int J Soc Psychiatry 2001; 47:67-77
76. Borge L, Martinsen EW, Ruud T, et al. Quality of life, loneliness, and social contact among long-term psychiatric patients. Psychiatr Serv 1999; 50:81-4
77. Hansson L, Eklund M, Bengtsson-Tops A. The relationship of personality dimensions as measured by the temperament and character inventory and quality of life in individuals with schizophrenia or schizoaffective disorder living in the community. Qual Life Res 2001; 10:133-9
78. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl) 2002; 162:3-10
79. Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43:135-45
80. Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002; 57:201-8
81. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290:2693-702
82. de Haan L, Peters B, Dingemans P, et al. Attitudes of patients toward the first psychotic episode and the start of treatment. Schizophr Bull 2002; 28:431-42
83. Voruganti LN, Heslegrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185:463-5
84. Dollfus S, Ribeyre JM, Petit M. Objective and subjective extrapyramidal side effects in schizophrenia: their relationships with negative and depressive symptoms. Psychopathology 2000; 33:125-30
85. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995; 10 (Suppl. 3):105-14